Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Phase 3

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Orforglipron
Drug: Dapagliflozin

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 888

Registration Number: NCT06192108

Locations: 🇨🇳
The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇩🇪
Diabetologische Schwerpunktpraxis und Praxis für Allgemeinmedizin Dr. Veronika Wenzl-Bauer u. Dr. Josef We -T, Rehlingen, Saarland, Germany
🇵🇱
Ekamed, Lublin, Lubelskie, Poland

and more 73 locations

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

Phase 1

Completed

Conditions: Healthy
Hepatic Insufficiency

Interventions: Drug: Pirtobrutinib

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT06190691

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Pinnacle Clinical Research, San Antonio, Texas, United States
🇺🇸
Orange County Research Institute, Anaheim, California, United States

and more 5 locations

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

Phase 1

Completed

Conditions: Healthy
Renal Insufficiency

Interventions: Drug: Pirtobrutinib

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT06190678

Locations: 🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
🇺🇸
Orange County Research Institute, Anaheim, California, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 2 locations

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Phase 1

Completed

Conditions: Healthy
Obese
Overweight

Interventions: Drug: Orforglipron
Drug: Simvastatin
Drug: Digoxin
Drug: Rosuvastatin
Drug: Acetaminophen
Drug: Midazolam
Drug: Sodium Bicarbonate

First Posted Date: 2024-01-02

Last Posted Date: 2024-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 50

Registration Number: NCT06186622

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States

A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pirtobrutinib

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT06180980

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

A Study of LY3410738 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3410738
Drug: Placebo

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT06181045

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3410738
Drug: Esomeprazole

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT06181084

Locations: 🇺🇸
Labcorp Clinical Research, Daytona Beach, Florida, United States

A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pirtobrutinib

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT06181006

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam Solution
Drug: Midazolam Syrup
Drug: Pirtobrutinib

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 15

Registration Number: NCT06180967

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-LOXO-305
Drug: LOXO-305

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 9

Registration Number: NCT06180954

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy